Description
Technical Overview
CJC-1295 (No DAC) + GHRP-6 (5 mg / 5 mg) is a research peptide blend designed for laboratory investigation of growth hormone secretagogue pathways and pulsatile signaling. The combination is commonly examined in controlled research settings for its role in studying synergistic GHRH analog and ghrelin-receptor agonist activity.
CJC-1295 (No DAC), also known as Modified GRF (1-29), is a growth hormone releasing hormone (GHRH) analog — a 29-amino-acid peptide carrying four substitutions (D-Ala2, Gln8, Ala15, Leu27) that improve its stability against enzymatic degradation. It is utilized for research into pituitary stimulation mechanisms. GHRP-6 is a first-generation synthetic hexapeptide ghrelin/GHS-R1a receptor agonist studied for its effect on growth hormone secretory signaling pathways and for its pronounced ghrelin-mimetic activity in appetite-signaling research models. When studied together, these compounds are frequently used in peptide research protocols exploring complementary mechanisms of action on GH-axis modulation under controlled experimental conditions.
The blend is synthesized using solid-phase peptide synthesis (SPPS) and purified by HPLC to achieve high analytical purity suitable for research and assay applications.
Specifications
Compound Name: CJC-1295 (No DAC) + GHRP-6
Strength: 5 mg / 5 mg per vial
CJC-1295 (No DAC) Molecular Formula: C152H252N44O42 (Molecular Weight: ~3,367.9 g/mol)
GHRP-6 Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
GHRP-6 Molecular Formula: C46H56N12O6 (Molecular Weight: ~873.0 g/mol)
Format: Lyophilized solid
Purity: ≥ 99% (Mass Spectrometry Verified)
Reconstitution: Recommended for laboratory titration using bacteriostatic water.
Notice
American Peptides provides this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments.
For Research Use Only. This product is not for human or veterinary use of any kind.
Reviews
There are no reviews yet.